Press Releases

PDF viewPrint viewRSS FeedsEmail AlertSocial Media Sharing


Year:
Notify me when new press releases are posted to this site .
Press ReleasesMore Press Releases...
DateHeadlineFormat
10/21/2014Cubist Reports Third Quarter 2014 Financial Results
10/20/2014Cubist Pharmaceuticals Names Robert J. Perez Chief Executive Officer
10/14/2014Cubist to Announce Third Quarter 2014 Financial Results on Tuesday, October 21, 2014
10/08/2014Cubist to Present New Data from Study of fidaxomicin in Children with Clostridium Difficile-Associated Diarrhea at IDWeek 2014
9/30/2014Cubist to Present New Data on Antibiotics Portfolio at IDWeek 2014
9/18/2014Cubist Announces Continued Global Expansion with Opening of International Headquarters in Zurich
8/26/2014Cubist to Present New Data from Antibiotics Portfolio at 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
8/25/2014Cubist to Present at Morgan Stanley Global Healthcare Conference
8/22/2014Cubist Announces EMA Acceptance of Ceftolozane/Tazobactam Marketing Authorization Application for Review
8/08/2014Cubist Pharmaceuticals Issues Voluntary Nationwide Recall of Nine Lots of CUBICIN (daptomycin for injection) 500 mg in 10 mL single use vials Following Complaints of Foreign Particulate Matter in Reconstituted Vials
8/06/2014Cubist Pharmaceuticals Issues Voluntary U.S. Recall of Certain Lots of CUBICIN (daptomycin for injection) 500 mg in 10 mL single use vials Due to Presence of Particulate Matter
8/05/2014Cubist’s Once-daily SIVEXTRO™ (tedizolid phosphate) Available for Physician and Hospital Order in I.V. and Oral Formulations
 
 Source: SNL Financial LC
Optimer Press Releases
8/1/2013 Optimer Reports Second Quarter 2013 Financial Results
5/9/2013 Optimer Reports First Quarter 2013 Financial Results
4/26/2013 DIFICID® (fidaxomicin) Tablets Approved in Australia
2/28/2013 Optimer Reports Fourth Quarter and Fiscal Year 2012 Financial Results
More Optimer Press Releases...



Trius Press Releases
6/12/2013 Trius Therapeutics Announces Publication of Antibiotic Safety Study in Antimicrobial Agents and Chemotherapy
5/13/2013 Trius Announces Notice of Allowance of U.S. Patent Application Related to Tedizolid Phosphate Combination With Daptomycin
4/29/2013 Trius Therapeutics Presents Clinical Data on Experimental Antibiotic Tedizolid at ECCMID Meeting
4/23/2013 Trius Therapeutics to Present Experimental Antibiotic Study Results at ECCMID Meeting
More Trius Press Releases...

Copyright 2014, © SNL Financial LC  Terms of Use